Yu-Li Lo is a Distinguished Professor at the Institute of Pharmacology/Pharmacy, National Yang Ming Chiao Tung University, Taipei, Taiwan. She has garnered over three decades of expertise in nanomedicine, anticancer drugs, and biopharmaceutical dosage form design. Her research focuses on developing tumor microenvironment-responsive and tumor-targeting nanoparticles for chemotherapy and gene-based therapeutics. Prof. Lo excels in designing pH- and thermo-sensitive nanoparticles for delivering anticancer drugs and nucleic acids such as miRNAs, CRISPR/Cas, aptamers, siRNAs, and ASOs. Throughout her career, Prof. Lo has received numerous accolades, including the 2023 Potential Team Award from the National Biotechnology Research Park, the National Innovation Award in 2023, and the FUTEX Award from the National Science and Technology Council (NSTC) in Taiwan. She has also been recognized with the Best Paper/Poster Award from Veterans General Hospitals and the University System of Taiwan in 2023. Her contributions are further highlighted by four patents granted in both the USA and Taiwan. Prof. Lo's impact extends globally, having been ranked among the World’s Top 2% Lifelong Scientific Influence (1960–2022) and the World’s Top 2% Scientists from 2020 to 2022. She served as a member of the Chinese Pharmacopoeia Editing Advisory Council for the Ministry of Health and Welfare in Taiwan from 2017 to 2021. To foster international collaboration, she has been a visiting scholar at prestigious institutions including Caltech, New York University, and the University of North Carolina at Chapel Hill in the USA over the past five years.

Iman obtained his PhD in 2011 from the Lowy Cancer Research Centre at the University of New South Wales. He then joined The University of Queensland as a postdoctoral fellow in cancer research, where he spent seven years working on projects that spanned both basic science and industry applications in the field of breast cancer. In 2018, Iman joined the University of Tasmania as a Lecturer in Pharmaceutical Science and established his independent research group. His research focused on identifying potential therapeutic targets for brain cancers and cellular ageing, with an emphasis on targeting calcium signalling and metabolic pathways. In 2023, Iman moved to Monash University, where he took on a role as a Senior Lecturer in Pharmacology. His current research streams include drug discovery for medulloblastoma brain cancer in collaboration with clinicians, the identification of novel targets for controlling cellular senescence, and targeting therapy-induced senescence in cancer.

Mr Zheng Zheng is a PhD candidate in the School of Pharmacy at the University of Queensland studying under Dr. Jared Miles. Before candidature, he completed a Master of Biotechnology degree from the Australian Institute for Bioengineering and Nanotechnology, University of Queensland. His current research interest includes oral dosage forms production using selective laser sintering technology, which is related to formulation selection, printing parameter optimisation, 3D model design, and post-printing tests.

Anna Krasilnikova graduated with a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree and later obtained her MD in Clinical Pharmacology at Volgograd State Medical University (VolgSMU), Russia. After obtaining her Ph.D. in the field of Clinical Pharmacology and Pharmacology in 2004 (VolgSMU) she started as Assistant professor in the Department of Clinical Pharmacology and Intensive Care and later headed the position of the director of Regional Center of Drug Safety Monitoring in Volgograd, Russia. From 2010 till 2023 Dr. Anna Krasilnikova held the position of Assoc. Prof of Pharmacology at the Faculty of Medicine Universiti Teknologi MARA (Malaysia). Since June 2023 she is Associate Professor of Pharmacology, at the department of Pathology and Pharmacology, School of Medicine, IMU University (Malaysia) and adjunct Associate Professor department of Clinical Pharmacology and Intensive care of Volgograd State Medical University (Russia). Her research interests include experimental and clinical pharmacology of antiviral and antibacterial drugs, ocular Pharmacology and drug development. Currently, she is focused on the investigation of new antiviral drugs against Dengue and Chikungunya virus and antimicrobial peptides. Anna Krasilnikova has more than 30 publications in indexed journals and chapters in books and she presented her research findings at various national and international conferences. She is a member of British Pharmacology Society and Malaysian Society of Pharmacology and Physiology.